Century Therapeutics (IPSC) Other Operating Expenses (2020 - 2026)

Century Therapeutics (IPSC) has reported Other Operating Expenses for 5 consecutive years, with $29.3 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Other Operating Expenses changed N/A year-over-year to $29.3 million; the TTM figure through Mar 2026 stood at $29.3 million (up 576.61% YoY), while the FY2025 annual figure was $6.8 million, up 56.3% from the prior year.
• Other Operating Expenses improved to $29.3 million in Q3 2025 per IPSC's latest filing, from $4.3 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $29.3 million in Q3 2025 and bottomed at $4.0 million in Q3 2023.
• Historically, Other Operating Expenses has averaged $10.8 million across 4 years, with a median of $7.2 million in 2022.
• On a YoY basis, Other Operating Expenses climbed as much as 67.08% in 2024 and fell as far as 67.08% in 2024.
• Century Therapeutics' Other Operating Expenses stood at $10.0 million in 2022, then soared by 31.45% to $13.1 million in 2023, then tumbled by 67.08% to $4.3 million in 2024, then soared by 576.61% to $29.3 million in 2025.
• Business Quant data shows IPSC's Other Operating Expenses at $29.3 million in Q3 2025, $4.3 million in Q4 2024, and $13.1 million in Q4 2023.